UNSPSC 51273005: Diperodon

This classification denotes an anesthetic agent with the molecular formula C22H27N3O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2456GO94TR, chemically known as 1,2-propanediol, 3-piperidino-, dicarbanilate (ester), monohydrochloride but generally known as diperodon, which bears US NIH Compound Identifier 10831. European Medicines Agency schedules Diperodon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07207MIG.

UNSPSC 51273005 Diperodon is a Commodity code under which state and local governments procure pharmaceutical products, specifically naloxone, opioid antagonists, and related drug-management systems for emergency response and community health initiatives. The work involves supplying finished pharmaceutical inventory to public health departments, health-and-human-services agencies, and county health facilities on regular delivery schedules, often with quarterly or scheduled replenishment cycles. Issuing bodies include county health departments, state health-and-human-services commissions, and cooperative purchasing alliances serving multiple states and local jurisdictions. Procurement approaches vary from competitive IFBs for direct purchase of finished units to RFIs and RFPs seeking vendor capacity to supply through authorized wholesalers or direct-to-manufacturer channels.

Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to its Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs that could bypass traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with responses due March 26, 2026 and awards effective July 1, 2026; the RFP weighted price competitiveness at 75 percent and required vendors to maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Recent activity concentrates in Florida, Texas, and the Upper Midwest, with cooperative purchasing vehicles and state-level procurement offices driving volume beyond single-county acquisitions.